Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JYLAMVO vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Treatment of severe, active rheumatoid arthritis in adults,Treatment of polyarticular-course juvenile idiopathic arthritis in children,Treatment of severe psoriasis in adults
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life is 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Methotrexate is primarily metabolized in the liver to polyglutamated forms, which are retained intracellularly. It undergoes hepatic metabolism via aldehyde oxidase and xanthine oxidase. Renal excretion is the major elimination route.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Primarily renal elimination as unchanged drug (approximately 70-80%) with minor biliary/fecal excretion (20-30%).
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Approximately 85-90% bound primarily to albumin and alpha-1-acid glycoprotein.
47% bound to plasma proteins (primarily albumin)
Volume of distribution is 0.6-1.2 L/kg, indicating distribution into total body water and some tissue binding.
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
Oral bioavailability is 60-75% due to first-pass metabolism; absolute bioavailability is 70%.
IV: 100% (only IV route); oral: not approved
No dose adjustment is recommended for patients with mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl 15-29 m L/min), reduce dose to 20 mg twice daily. For end-stage renal disease (Cr Cl <15 m L/min) or on dialysis, not recommended due to lack of data.
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
For patients with mild hepatic impairment (Child-Pugh A), no dose adjustment. For moderate hepatic impairment (Child-Pugh B), reduce dose to 20 mg twice daily. For severe hepatic impairment (Child-Pugh C), not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
Safety and efficacy in pediatric patients have not been established; no recommended dosage.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
No specific dose adjustment required based on age alone; monitor for increased risk of adverse events (e.g., myelosuppression, infections) as elderly patients may have decreased organ function and comorbidities.
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
JYLAMVO can cause severe or fatal toxicities including hepatotoxicity, myelosuppression, pulmonary fibrosis, and renal failure. It is contraindicated in pregnancy (teratogenic) and in nursing mothers. Fatal toxicity has been reported with concomitant NSAID use. Monitoring for toxicity and appropriate dosing adjustments are required.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Hepatotoxicity (monitor liver function), myelosuppression (monitor CBC), pulmonary toxicity (interstitial pneumonitis), renal toxicity (monitor renal function), gastrointestinal toxicity, neurotoxicity, infections, and tumor lysis syndrome. Corticosteroids or other immunosuppressants may increase risk of infection.
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
Hypersensitivity to methotrexate, severe hepatic impairment, severe renal impairment, severe anemia, leukopenia, thrombocytopenia, pregnancy, breastfeeding, alcoholism, pre-existing immunodeficiency syndromes, and concurrent use of NSAIDs in patients with renal impairment.
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
No specific food interactions are known. Administer without regard to meals. Maintain adequate hydration.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
JYLAMVO (methotrexate) is contraindicated in pregnancy. It is an abortifacient and teratogen. First trimester exposure causes multiple congenital anomalies (craniofacial, limb, CNS defects) and spontaneous abortion. Second and third trimester use may cause fetal growth restriction, developmental delay, and potential methotrexate syndrome. Use effective contraception during and for at least 3 months after treatment.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
Contraindicated during breastfeeding. Methotrexate is excreted into breast milk in low concentrations (M/P ratio 0.6-1.1), but due to potential for serious adverse effects (immunosuppression, neutropenia, developmental toxicity) in the nursing infant, breastfeeding is not recommended. Discontinue breastfeeding or avoid JYLAMVO.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
Not applicable. JYLAMVO is contraindicated in pregnancy. No dose adjustments exist as it should not be used during pregnancy. Discontinue immediately if pregnancy occurs.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
JYLAMVO (amivantamab) is a bispecific EGFR-MET antibody for EGFR exon 20 insertion mutation-positive NSCLC. Monitor for infusion-related reactions (premedicate with antihistamines, antipyretics, and corticosteroids). Assess for interstitial lung disease (ILD) prior to each dose; withhold for suspected ILD. Check serum albumin and electrolytes before treatment; hypoalbuminemia increases risk of toxicities. Advise use of sunscreen and sun protective measures due to photosensitivity risk.
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
JYLAMVO is given as an intravenous infusion over 2-4 hours, typically every 2 weeks after an initial loading dose.,You may experience infusion reactions; symptoms include fever, chills, nausea, or shortness of breath. Tell your nurse immediately if these occur.,This drug can cause lung inflammation (ILD); report any new or worsening cough, chest pain, or difficulty breathing.,Avoid prolonged sun exposure; use broad-spectrum sunscreen (SPF 30+) and wear protective clothing.,Your doctor will monitor your blood counts and kidney function regularly during treatment.
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
No interactions on record
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JYLAMVO vs CLOFARABINE, answered by our medical review team.
JYLAMVO is a Antineoplastic Agent that works by JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JYLAMVO and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JYLAMVO is: Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JYLAMVO and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JYLAMVO is classified as Category C. JYLAMVO (methotrexate) is contraindicated in pregnancy. It is an abortifacient and teratogen. First trimester exposure causes multiple congenital anomalies (craniofacial, limb, CNS. CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.